UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB








[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
    OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2003


[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934 For the transition period from            to
                                                       ------------  -----------
Commission File Number: 000-31567


                           Rapid Bio Tests Corporation
                           ---------------------------
        (Exact name of small business issuer as specified in its charter)

Nevada                                                                35-0511303
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

                   5409 Ivy Street, Springfield, Oregon 97478
--------------------------------------------------------------------------------
                    (Address of principal executive offices)


                                  (541)686.5989
                                  -------------
                           (Issuer's Telephone Number)



                      APPLICABLE ONLY TO CORPORATE ISSUERS


State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date. As of August 31, 2003 there were
20,564,214 shares of the issuer's $.001 par value common stock issued and
outstanding.



                                       1
<PAGE>



ITEM 1.  FINANCIAL STATEMENTS
-----------------------------



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)

                              FINANCIAL STATEMENTS

                      August 31, 2003 and February 28, 2003












                                       2
<PAGE>


                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                                 Balance Sheets




                                     ASSETS
                                     ------
<TABLE>
<CAPTION>
<S>                                                                               <C>                  <C>
                                                                               August 31,        February 28,
                                                                                  2003                 2003
                                                                           -----------------     -----------------
                                                                               (Unaudited)

CURRENT ASSETS

   Cash                                                                    $               -     $               -
                                                                           -----------------     -----------------

     Total Current Assets                                                                  -                     -
                                                                           -----------------     -----------------

     TOTAL ASSETS                                                          $               -     $               -
                                                                           =================     =================


                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
                 ----------------------------------------------

CURRENT LIABILITIES

   Cash overdraft                                                          $              40     $               -
   Accounts payable                                                                   25,991                12,308
   Accounts payable - related parties                                                      -                40,941
   Accrued expenses                                                                   17,191                 5,000
   Note payable (Note 3)                                                              13,000                     -
                                                                           -----------------     -----------------

     Total Current Liabilities                                                        56,222                58,249
                                                                           -----------------     -----------------

     Total Liabilities                                                                56,222                58,249
                                                                           -----------------     -----------------

STOCKHOLDERS' EQUITY (DEFICIT)

   Common stock, par value $0.001; authorized
     120,000,000 shares; 20,564,214 and 114,214
     shares issued and outstanding, respectively                                      20,564                   114
   Additional paid-in capital                                                      2,907,658               795,537
   Prepaid services (Note 3)                                                         (42,552)                    -
   Deficit accumulated prior to the development stage                               (989,057)             (989,057)
   Deficit accumulated during the development stage                               (1,952,835)              135,157
                                                                           -----------------     -----------------

     Total Stockholders' Equity (Deficit)                                            (56,222)              (58,249)
                                                                           -----------------     -----------------

     TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY (DEFICIT)                                                     $               -     $               -
                                                                           =================     =================
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>




                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                            Statements of Operations
                                   (Unaudited)


<TABLE>
<CAPTION>
<S>                                <C>                                           <C>                     <C>
                                                                                                        From
                                                                                                      Inception
                                                                                                       Of the
                                                                                                     Development
                                                                                                      Stage on
                             For the Three Months Ended             For the Six Months Ended           March 1
                                       August 31,                          August 31,               2001 through
                           ----------------------------------  ---------------------------------     August 31,
                                  2003             2002                 2003          2002              2003
                           ----------------  ----------------  ---------------   ---------------  ----------------

REVENUES                   $              -  $              -  $             -   $             -  $              -
                           ----------------  ----------------  ---------------   ---------------  ----------------

EXPENSES

     Officer salaries                24,000                 -           24,000                 -            24,000
     Consulting Fees              2,028,448                 -        2,028,448                 -         2,028,448
     General and Administrative      32,181             1,122           35,005             4,377            76,843
                           ----------------  ----------------  ---------------   ---------------  ----------------

Total Expenses                    2,084,629             1,122        2,087,453             4,377         2,129,291
                           ----------------  ----------------  ---------------   ---------------  ----------------

LOSS FROM OPERATIONS             (2,084,629)           (1,122)      (2,087,453)           (4,377)       (2,129,291)
                           ----------------  ----------------  ---------------   ---------------  ----------------

OTHER INCOME (EXPENSE)

     Gain on extinguishments of
     debt                                 -                 -                -                 -           189,233
     Interest expense                   (41)             (450)            (539)             (900)          (12,777)
                           ----------------  ----------------  ---------------   ---------------  ----------------

     Total Other Income
     (Expense)                          (41)             (450)            (539)             (900)          176,456
                           ----------------  ----------------  ---------------   ---------------  ----------------

INCOME (LOSS) BEFORE
 INCOME TAXES                    (2,084,670)           (1,572)      (2,087,992)           (5,277)       (1,952,835)

     Income taxes                         -                 -                -                 -                 -
                           ----------------  ----------------  ---------------   ---------------  ----------------

NET (LOSS)                 $     (2,084,670) $         (1,572) $    (2,087,992)  $        (5,277) $     (1,952,835)
                           ================  ================  ===============   ===============  ================

BASIC LOSS PER SHARE:      $          (0.14) $          (0.02) $         (0.26)  $         (0.05)
                           ================  ================  ===============   ===============

WEIGHTED AVERAGE
 NUMBER OF SHARES
 OUTSTANDING                     15,498,392           102,188        7,987,260           114,188
                           ================  ================  ===============   ===============
</TABLE>

  The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                  Statements of Stockholders' Equity (Deficit)

<TABLE>
<CAPTION>
                                                                                                        Deficit         Deficit
                                                                                                      Accumulated     Accumulated
                                                           Common                   Additional       Prior to the     During the
------------------------------------------------------------------------------        Paid-in         Development     Development
                                                  Shares            Amount            Capital           Stage            Stage
-------------------------------------------------------------  ---------------   ----------------  ---------------  ---------------
<S>                                                 <C>              <C>                <C>               <C>              <C>
Balance, February 28, 2001                             39,614  $            39   $        563,971  $      (989,057) $             -

Common stock issued in satisfaction
 of debt at $0.123 per share,
 December 17, 2001                                      7,000                7            214,734                -                -

Common stock issued in satisfaction
 of debt at $0.001 per share,
 January 28, 2002                                       4,000                4                996                -                -

Common stock issued for services
 at $0.001 per share,
 February 1, 2002                                      63,600               64             15,836                -                -

Net income for the year ended
 February 28, 2002                                          -                -                  -                -           90,714
                                             ----------------  ---------------   ----------------  ---------------  ---------------

Balance, February 28, 2002                            114,214              114            795,537         (989,057)          90,714

Net income for the year ended
 February 28, 2003                                          -                -                  -                -           44,443
                                             ----------------  ---------------   ----------------  ---------------  ---------------

Balance, February 28, 2003                           114, 214              114            795,537         (989,057)         135,157

Common stock issued for assets at
  predecessor cost of $0.00 per share
  on June 19, 2003 (unaudited)                     15,000,000           15,000            (15,000)               -                -

Common stock issued for consulting
  services at $0.38 per share on
  July 24, 2003 (unaudited)                         5,450,000            5,450          2,065,550                -                -

Assumption and forgiveness of debt
  by related parties (unaudited)                            -                -             61,571                -                -

Net loss for the six months ended
 August 31, 2003 (unaudited)                                -                -                  -                -       (2,087,992)
                                             ----------------  ---------------   ----------------   --------------  ---------------

Balance, August 31, 2003 (unaudited)               20,564,214  $        20,564   $      2,907,658   $     (989,057) $    (1,952,835)
                                             ================  ===============   ================   ==============  ================
</TABLE>

  The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>


                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                            Statements of Cash Flows
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                                         From
                                                                                                       Inception
                                                                                                        Of the
                                                                                                      Development
                                                                                                       Stage on
                                                                    For the Six Months Ended           March 1,
                                                                           August 31,                2001 through
                                                               ---------------------------------      August 31,
                                                                        2003          2002               2003
                                                               ---------------   ---------------  ----------------
<S>                                                                  <C>               <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES

   Net loss                                                    $    (2,087,992)  $        (5,277) $     (1,952,835)
   Adjustments to reconcile loss from operations
    to net cash used by operating activities:
     Gain on extinguishments of debt                                         -                 -          (189,233)
     Common stock issued for services                                2,028,448                 -         2,044,348
   Changes in assets and liabilities:
     Increase in accrued interest                                           41               900            10,388
     Increase in accounts payable and
      accounts payable - related parties                                34,313             4,377            57,142
     Increase in accrued expenses                                       12,150                 -            17,150
                                                               ---------------   ---------------  ----------------

       Net Cash Used by Operating Activities                           (13,040)                -           (13,040)
                                                               ---------------   ---------------  ----------------

CASH FLOWS FROM INVESTING ACTIVITIES                                         -                 -                 -
                                                               ---------------   ---------------  ----------------

   Proceeds from cash overdraft                                             40                 -                40
   Proceeds from loan                                                   13,000                 -            13,000
                                                               ---------------   ---------------  ----------------

     Net cash provided by financing activities                          13,040                 -            13,040
                                                               ---------------   ---------------  ----------------

CASH FLOWS FROM FINANCING ACTIVITIES

NET INCREASE (DECREASE) IN CASH                                              -                 -                 -

CASH AT BEGINNING OF PERIOD                                                  -                 -                 -
                                                               ---------------   ---------------  ----------------

CASH AT END OF PERIOD                                          $             -   $             -  $              -
                                                               ===============   ===============  ================

SUPPLEMENTAL CASH FLOW INFORMATION:

   Cash paid for:

     Interest                                                  $             -   $             -  $              -
     Income taxes                                              $             -   $             -  $              -

NON-CASH FINANCING AND INVESTING ACTIVITIES:

     Common stock issued in lieu of debt                       $             -   $             -  $        215,741
     Common stock issued for services                          $     2,028,448   $             -  $      2,044,348
</TABLE>

  The accompanying notes are an integral part of these financial statements.

                                       6
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                        Notes to the Financial Statements
                      August 31, 2003 and February 28, 2003


NOTE 1 -     BASIS OF FINANCIAL STATEMENT PRESENTATION

             The accompanying unaudited condensed financial statements have been
             prepared by the Company pursuant to the rules and regulations of
             the Securities and Exchange Commission. Certain information and
             footnote disclosures normally included in financial statements
             prepared in accordance with accounting principles generally
             accepted in the United States of America have been condensed or
             omitted in accordance with such rules and regulations. The
             information furnished in the interim condensed financial statements
             include normal recurring adjustments and reflects all adjustments,
             which, in the opinion of management, are necessary for a fair
             presentation of such financial statements. Although management
             believes the disclosures and information presented are adequate to
             make the information not misleading, it is suggested that these
             interim condensed financial statements be read in conjunction with
             the Company's most recent audited financial statements and notes
             thereto included in its February 28, 2003 Annual Report on Form
             10-KSB. Operating results for the six months ended August 31, 2003
             are not necessarily indicative of the results that August be
             expected for the year ending February 28, 2004.

NOTE 2 -      GOING CONCERN

              The Company's financial statements are prepared using accounting
              principles generally accepted in the United States of America
              applicable to a going concern which contemplates the realization
              of assets and liquidation of liabilities in the normal course of
              business. The Company currently has minimal operations and has
              incurred significant losses which have resulted in an accumulated
              deficit of $2,941,892 at August 31, 2003 which raises substantial
              doubt about the Company's ability to continue as a going concern.
              The accompanying financial statements do not include any
              adjustments relating to the recoverability and classification of
              asset carrying amounts or the amount and classification of
              liabilities that might result from the outcome of this
              uncertainty.

              It is the intent of management to continue to work to develop
              rapid diagnostic testing technology, platforms, that will be used
              for the development and manufacturing of an array of rapid
              diagnostic tests. The initial tests that the company is proposing
              to develop include; West Nile Virus, Hepatitis B, HIV 1 and 2,
              Tuberculosis, Bubonic Plague, and the the four strains of Malaria.
              Until this occurs, the Company's management intends to provide the
              Company with sufficient working capital to cover its operating
              expenses. However, there is no assurance that the Company's plans
              will be successful or that the Company's management will continue
              to provide sufficient capital to cover the operating expenses of
              the Company.

NOTE 3 -      MATERIAL EVENTS

              Related Party Transactions
              --------------------------

              During the three months ended August 31, 2003, the former officers
              and directors of the Company forgave and assumed the $61,571 of
              the Company's debt. This amount has been recorded as a
              contribution of capital.


                                       7
<PAGE>



NOTE 3 -      MATERIAL EVENTS (Continued)

              Reverse Stock Split
              -------------------

              On April 25, 2003, the Company consummated a reverse split of its
              issued and outstanding common stock on a 1-for-250 basis. As a
              result of the stock split, each two hundred fifty (250) shares of
              the Company's issued and outstanding common stock was decreased to
              one (1) fully paid and nonassessable share of common stock, $0.001
              par value per share. Fractional shares were rounded upward. The
              reverse stock split reduced the number of shares of common stock
              outstanding from 28,546,972 shares as of April 24, 2003, to
              approximately 114,214 shares. The par value of the common stock
              did not change. The shares of common stock have been retroactively
              restated in the financial statements for the reverse split for all
              periods presented.

              Name Change
              -----------

              On June 12, 2003, the Company changed its corporate name from
              Vitatonics Corp. to Rapid Bio Tests Corporation. The name change
              became effective with the filing of a Certificate of Amendment to
              the Company's Articles of Incorporation with the Nevada Secretary
              of State. The Company changed its name to reflect a change in its
              business focus.

              Increase in authorized common stock
              -----------------------------------

              On June 12, 2003, the Company filed an Amendment to its Articles
              of Incorporation, which increased its authorized number of shares
              of its $.001 par value common stock from 50,000,000 to
              120,000,000.

              The name change, reverse split and increase in authorized shares
              of common stock were approved on April 25, 2003, by unanimous
              approval of the Company's Board of Directors. In addition, on
              April 25, 2003, shareholders holding a majority of the Company's
              outstanding common stock approved those actions by written consent
              in lieu of a meeting in accordance with the relevant sections of
              the Nevada Revised Statutes.

              Change of Symbol and CUSIP Number
              ---------------------------------

              Concurrent with the above actions, the Company was issued a new
              symbol and CUSIP Number. The Company's symbol changed from "VITN"
              to "RBIO," and its CUSIP Number has changed from 928488-10-5 to
              753339-10-0.

              Resignations
              ------------

              On June 16, 2003, the following occurred: (i) Daniel McCormick
              resigned as the President and director of the Company; (ii) George
              Farquhar (effective August 23, 2003) resigned as the Secretary,
              Chief Financial Officer and director of the Company; and (iii)
              Dennis McCormick resigned as director of the Company. None of the
              resignations were the result of any disagreement with the Company
              on any matter relating to the Company's operations, policies or
              practices.


                                       8
<PAGE>


NOTE 3 -      MATERIAL EVENTS (Continued)

              Appointment of New Officers and Directors
              -----------------------------------------

              On June 16, 2003, the following occurred: (i) Geoffrey V.F.
              Seaman, Ph.D. was appointed as President,  Chief Executive
              Officer and a director of the Company; (ii) Paul Hemmes, Ph.D.
              was appointed as Secretary, Treasurer, Chief Financial
              Officer and a director of the Company; and (iii) David H.
              Regan, M.D. was appointed as Vice President of Medical
              Affairs and a director of the Company.

              Stock Issuances
              ---------------

              On June 16, 2003, Drs. Seaman, Hemmes and Regan executed
              Employment and Asset Purchase Agreements (the "Agreements"). The
              purpose of the Agreements was to retain their management and
              technical services, including their intellectual property
              necessary to develop the Company's proposed medical testing
              products. Pursuant to the Agreements, the Company issued 9,000,000
              shares of its common stock to Dr. Seaman, 4,000,000 shares of its
              common stock to Dr. Hemmes, and 2,000,000 shares of its common
              stock to Dr. Regan in exchange and certain intellectual property
              necessary to develop the Company's proposed products and
              processes. The value of the shares issued in exchange for
              the intellectual property were valued at $0.00 which represented
              predecessor cost.

              With the assistance of its new management and the intellectual
              property transferred under the Agreements, the Company intends to
              develop, manufacture and market a series of diagnostic tests that
              can be used to detect a variety of human diseases and conditions,
              and which have utility in a variety of veterinary and agricultural
              products. The Company believes that rapid, sensitive, accurate and
              reliable diagnostic tests are necessary to respond to epidemics,
              bio-terrorism attacks and simply to cut the current high cost of
              diagnostics for general health care.

              On July 24, 3003, the Company issued 5,450,000 shares of common
              stock for services to nine (9) individuals valued at the closing
              price on the date of issue or $0.38 per share. Total consideration
              value of the issuances was $2,071,000. The Company expensed
              $2,028,448 of the share value and allocated $42,552 to prepaid
              services which will be expensed ratably over a 12 month period.

              Note Payable
              ------------

              The Company received $13,000 from unrelated third parties during
              the quarter ended August 31, 2003. No terms on the notes have been
              established yet.

              2003 Stock Option Plan
              ----------------------

              On August 26, 2003, the Company adopted and approved the 2003
              stock option plan. The plan is intended to help attract and retain
              the services of persons now performing services for the Company.
              The shares purchased under this plan cannot exceed in aggregate,
              30% of the issued and outstanding common stock of the Company. The
              exercise price for each issuance will be determined by the
              Company.


NOTE 4 -      SUBSEQUENT EVENT

              On September 9, 2003, the Company approved the issuance of 100,000
              options as payment for services. The options are exercisable at
              $0.65 per share.

                                       9
<PAGE>



ITEM 2.  PLAN OF OPERATION
--------------------------

THIS FOLLOWING INFORMATION SPECIFIES CERTAIN FORWARD-LOOKING STATEMENTS OF
MANAGEMENT OF THE COMPANY. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT
ESTIMATE THE HAPPENING OF FUTURE EVENTS AND ARE NOT BASED ON HISTORICAL FACT.
FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING
TERMINOLOGY, SUCH AS "MAY", "SHALL", "WILL", "COULD", "EXPECT", "ESTIMATE",
"ANTICIPATE", "PREDICT", "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", OR
SIMILAR TERMS, VARIATIONS OF THOSE TERMS OR THE NEGATIVE OF THOSE TERMS. THE
FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION HAVE BEEN
COMPILED BY OUR MANAGEMENT ON THE BASIS OF ASSUMPTIONS MADE BY MANAGEMENT AND
CONSIDERED BY MANAGEMENT TO BE REASONABLE. OUR FUTURE OPERATING RESULTS,
HOWEVER, ARE IMPOSSIBLE TO PREDICT AND NO REPRESENTATION, GUARANTY, OR WARRANTY
IS TO BE INFERRED FROM THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE FORWARD-LOOKING STATEMENTS SPECIFIED IN
THE FOLLOWING INFORMATION REPRESENT ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT
TO UNCERTAINTY AS TO POSSIBLE CHANGES IN ECONOMIC, LEGISLATIVE, INDUSTRY, AND
OTHER CIRCUMSTANCES. AS A RESULT, THE IDENTIFICATION AND INTERPRETATION OF DATA
AND OTHER INFORMATION AND THEIR USE IN DEVELOPING AND SELECTING ASSUMPTIONS FROM
AND AMONG REASONABLE ALTERNATIVES REQUIRE THE EXERCISE OF JUDGMENT. TO THE
EXTENT THAT THE ASSUMED EVENTS DO NOT OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY
FROM ANTICIPATED OR PROJECTED RESULTS, AND, ACCORDINGLY, NO OPINION IS EXPRESSED
ON THE ACHIEVABILITY OF THOSE FORWARD-LOOKING STATEMENTS. WE CANNOT GUARANTY
THAT ANY OF THE ASSUMPTIONS RELATING TO THE FORWARD-LOOKING STATEMENTS SPECIFIED
IN THE FOLLOWING INFORMATION ARE ACCURATE, AND WE ASSUME NO OBLIGATION TO UPDATE
ANY SUCH FORWARD-LOOKING STATEMENTS.

CRITICAL ACCOUNTING POLICY AND ESTIMATES. Our Management's Discussion and
Analysis of Financial Condition and Results of Operations section discusses our
financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States of America. The preparation
of these financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. On an on-going basis, management evaluates
its estimates and judgments, including those related to revenue recognition,
accrued expenses, financing operations, and contingencies and litigation.
Management bases its estimates and judgments on historical experience and on
various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different
assumptions or conditions. The most significant accounting estimates inherent in
the preparation of our financial statements include estimates as to the
appropriate carrying value of certain assets and liabilities which are not
readily apparent from other sources. These accounting policies are described at
relevant sections in this discussion and analysis and in the notes to the
financial statements included in our Quarterly Report on Form 10-QSB for the
period ended August 31, 2003.

OUR BUSINESS.  On June 16, 2003, we entered into  Employment  and Asset Purchase
Agreements with Dr.  Geoffrey  Seaman,  Dr. Paul Hemmes,  and Dr. David Regan to
retain their management and technical  services and to purchase the intellectual
property necessary to develop our proposed medical testing products. Pursuant to
these  agreements,  we issued thirty  million  shares of our common stock to Dr.
Seaman,  to Dr.  Hemmes,  and to Dr.  Regan in  exchange  for  their  management
services  and certain  intellectual  property  necessary to develop our proposed
products and processes.  With the assistance of our new management, we intend to
develop,  manufacture  and  market a series of rapid,  sensitive,  accurate  and
reliable diagnostic tests that can be used to detect a variety of human diseases
and  conditions,  and  which  have  utility  in  a  variety  of  veterinary  and
agricultural products. We believe that diagnostic tests are necessary to respond
to epidemics,  bio-terrorism  attacks and simply to cut the current high cost of
diagnostics for general health care.

Our current management has examined a wide range of current technologies used
for rapid identification of microorganisms and toxic agents, but believes that
cutting edge and high tech approaches are unproven on a large scale and do not
meet the needs of today's environment. For these reasons, we will focus our
efforts on established technology. We propose to develop a panel of rapid,
accurate, robust and easy to perform tests for field assays and point-of-care
testing. We also propose to develop a product line of tests for the rapid and
definitive detection of infectious diseases including bacterial and viral
pathogens, as well as toxins, which our management believes can be met by rapid
latex agglutination slide tests for the primary on-site identification. We
believe that such tests are simple, easy to manufacture, inexpensive and do not
require instrumentation or electricity, nor are highly trained personnel
necessary to read the test results.



                                       10
<PAGE>



We intend to develop and bring to the market place a series of diagnostic tests
for various diseases and conditions using a latex-based technology that is novel
and proprietary. We plan to make use of technology that is protected by existing
patent applications and our management believes that the key steps in the
process are virtually impossible to reverse engineer. Our current management has
agreed to take the necessary steps to ensure that all intellectual property
necessary to conduct such tests, including patents, is transferred to us. Our
management believes that such rapid latex-based diagnostic tests represent an
effective, simple, inexpensive and versatile analysis method, which is robust,
technically mature and usable in the field. Our management believes that broad
applications for this type of testing technology include identification of
infectious diseases originating from epidemics, acts of terrorism or individual
cases at point- of- care facilities. Our management anticipates that the latex
technology platform is also broadly applicable in the medical, veterinary,
agricultural and water diagnostic test markets. Our management believes that
rapid latex tests have major advantages over many other diagnostic test
approaches in speed and costs. In the estimation of our management, such test
technology will translate to less expensive delivery of health care, not only to
the American public and other developed nations, but also in developing nations.
Because rapid latex diagnostic tests do not require laboratory facilities or
electrical power, our management believes these types of tests are ideally
suited for field-testing or use by first responders or various emergency
personnel.

We believe that an appropriate combination of the technology inventions,
identification of ideal target markets, coupled with the basic capabilities of
the principals will enable us to achieve our objectives and rapidly reduce the
latex technology platforms to practice, allowing us to proceed to
commercialization and sale of our products.

FOR THE THREE MONTH PERIOD ENDED AUGUST 31, 2003.
-------------------------------------------------

LIQUIDITY AND CAPITAL RESOURCES. We had no cash or other current assets as at
August 31, 2003, and no total assets as at August 31, 2003. Our total current
liabilities were $56,222 at August 31, 2003, which was represented by accounts
payable of $25,991, $17,191 in accrued expenses, $13,000 represented by a note
payable and $40 in cash overdraft. At August 31, 2003, our liabilities exceeded
our assets by $56,222.

RESULTS OF OPERATIONS.

REVENUES. From inception of the development stage on March 1, 2001 through
August 31, 2003 we have not realized any revenues. We hope to generate revenues
in the next twelve months by actively pursuing our newly adopted business plan
and by the eventual sale of our planned line of diagnostic testing products.
However, we cannot guarantee that our products will be ready for sale or that we
will earn any revenues within the next twelve months.

OPERATING EXPENSES. For the three months ended August 31, 2003, our total
operating expenses were $2,084,629 compared to total expenses of $1,122 for the
corresponding period in 2002. The expenses for the three months ended August 31,
2003 was represented by $24,000 in officer salaries, $2,028,448 in consulting
fees and $32,181 in general and administrative expenses. This is in comparison
to the same period ending August 31, 2002, where we had operating expenses of
$1,122 which was represented solely by general and administrative expenses. The
large increase in operating expenses is due to incurring officer salaries and
consulting expenses, incurred as a result of operating under our new management
and business plan.

For the three months ending August 31, 2003, we also had an interest expense of
$41. Therefore our net loss was $2,084,670 for the three months ended August 31,
2003. This is in comparison to $450 in interest expenses for the three months
ending August 31, 2002. For the corresponding period ending in 2002, our net
loss was $1,572. Our net loss from operations from our inception of the
development stage on March 1, 2001 through to August 31, 2003 was $2,129,291.
However, our cumulative net loss from inception of the development stage on
March 1, 2001 through August 31, 2003 was $1,952,835 which was due to a gain of
$176,456 which we recognized on extinguishments of debt less interest expense of
$189,223, and interest expense of $12,777.



                                       11
<PAGE>



FOR THE SIX MONTH PERIOD ENDED AUGUST 31, 2003.
-----------------------------------------------

RESULTS OF OPERATIONS.

REVENUES. From inception of the development stage on March 1, 2001 through
August 31, 2003, we have not realized any revenues.

OPERATING EXPENSES. For the six months ended August 31, 2003, our total
operating expenses were $2,087,453 compared to total expenses of $4,377 for the
corresponding period in 2002. The expenses for the six months ended August 31,
2003 was represented by $24,000 in officer salaries, $2,028,448 in consulting
fees and $35,005 in general and administrative expenses. This is in comparison
to the same period ending August 31, 2002, where we had operating expenses of
$4,377 which was represented solely by general and administrative expenses. The
large increase in operating expenses is due to incurring officer salaries and
consulting expenses, incurred as a result of operating under our new management
and business plan.

For the six months ending August 31, 2003, we also had an interest expense of
$539. Therefore our net loss was $2,087,992 for the six months ended August 31,
2003. This is in comparison to $900 in interest expenses for the six months
ending August 31, 2002, making our net loss for the corresponding period ending
in 2002 a total of $5,277.

OUR PLAN OF OPERATION FOR THE NEXT TWELVE MONTHS. As of August 31, 2003, we had
no cash resources. We have not yet generated any revenues from operations. We
plan on raising additional operating funds through the sale of our common stock.
If we are not able to raise additional funds, we may arrange for loans or other
borrowings. Our forecast of the period of time through which our financial
resources will be adequate to support our operations is a forward-looking
statement that involves risks and uncertainties, and actual results could vary
as a result of a number of factors. There is no guarantee that we will be able
to sell shares of our common stock or that we will be able to arrange for
borrowings on acceptable terms if at all.

Our plan of operation is materially dependent on our ability to continue the
development of our proposed line of diagnostic tests and raise additional
capital to market our products. We believe that we will need approximately
$250,000 to continue to develop and then market our line of diagnostic testing
products. Within the next twelve months, we hope to begin the manufacturing and
marketing of our products. We must also enter into arrangements with
manufacturers to manufacture our planned product line. Finally, we must raise
additional working capital either through the sale of our common stock or
through loans. There is no guarantee that we will be able to raise additional
capital through the sale of our common stock. Moreover, there is no guarantee
that we will be able to arrange for loans on favorable terms, or at all.

Our inability to access the capital markets or obtain acceptable financing could
harm our results of operations and financial condition. To the extent that
additional capital is raised through the sale of equity or equity-related
securities, the issuance of such securities could result in dilution of our
stockholders. We cannot guaranty that additional funding will be available on
favorable terms. If adequate funds are not available within the next 12 months,
we may be required to limit our proposed diagnostic testing development
activities or to obtain funds through entering into arrangements with
collaborative partners. If adequate funds are not available, we believe that our
officers and directors will contribute funds to pay for our expenses. Our belief
that our officers and directors will pay our expenses is based on the fact that
our officers and directors collectively own 15,000,000 shares of our common
stock, which equals approximately 72.9% of our total issued and outstanding
common stock. We believe that our officers and directors will continue to pay
our expenses as long as they maintain their ownership of our common stock. If
our officers and directors loan us operating capital, we will either execute
promissory notes to repay the funds or issue stock to those officers and
directors. We have not formulated specific repayment terms. We will negotiate
the specific repayment terms and whether repayment will be in the form of stock
when, and if, funds are advanced by any of our officers and directors.



                                       12
<PAGE>



Over the next twelve months, we plan to continue with our ongoing research and
development activities to develop our proposed line of diagnostic tests.
Specifically, we are currently studying the development of rapid diagnostic
tests for Hepatitis B, West Nile Virus and a test to establish successful
vaccinations for small pox. Over the next twelve months, we do not anticipate
that we will purchase or sell any significant equipment, but rather, utilize the
facilities and equipment our scientific team currently has access to. In the
event that we are able to begin manufacturing operations, then we may need to
hire additional employees or independent contractors.

ITEM 3. CONTROLS AND PROCEDURES
-------------------------------

(a) Evaluation of disclosure controls and procedures. We maintain controls and
procedures designed to ensure that information required to be disclosed in the
reports that we file or submit under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission. Based upon
their evaluation of those controls and procedures performed within 90 days of
the filing date of this report, our chief executive officer and the principal
financial officer concluded that our disclosure controls and procedures were
adequate.

(b) Changes in internal controls. There were no significant changes in our
internal controls or in other factors that could significantly affect these
controls subsequent to the date of the evaluation of those controls by the chief
executive officer and principal financial officer.

                          PART II -- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
--------------------------

None.

ITEM 2. CHANGES IN SECURITIES.
------------------------------

Reference is made to our report on Form 8-K filed June 18, 2003, as referenced
below in Item 6, reporting our reverse stock split and increase in authorized
shares of common stock.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
----------------------------------------

None.

ITEM 4.  SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
----------------------------------------------------------

None.

ITEM 5.  OTHER INFORMATION
--------------------------

Reference is made to our report on Form 8-K filed June 18, 2003, as referenced
below in Item 6, reporting our name change, new CUSIP number and stock trading
symbol, resignation of directors, appointment of new officers and directors, and
employment/asset purchase agreements.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K
-----------------------------------------

A.  ON JUNE 18, 2003, WE FILED A REPORT ON FORM 8-K FILED A REPORT CONTAINING
THE INFORMATION BELOW:

ITEM 1. CHANGES IN CONTROL.
---------------------------

Concurrent with our name change on June 16, 2003, from Vitatonics Corp. to Rapid
Bio  Tests  Corporation,  Geoffrey  V.F.  Seaman,  Ph.D.  was  appointed  as our
President,  Chief Executive Officer and a director.  Additionally,  Paul Hemmes,
Ph.D. was appointed as our Secretary,  Treasurer,  Chief Financial Officer and a
director,  and David H. Regan,  M.D.  was  appointed  as our Vice  President  of
Medical  Affairs and a director.  Drs.  Seaman,  Hemmes and Regan also  executed
Employment  and Asset  Purchase  Agreements  dated  June 16,  2003  (the  "Asset
Purchase and Employment  Agreements").  The Agreements were attached to the Form
8-K filed on June 18, 2003 as Exhibits 2.1, 2.2, and 2.3.



                                       13
<PAGE>



ITEM 2. ACQUISITION OF ASSETS.
------------------------------

On June 16, 2003, we entered into Agreements with Dr. Geoffrey Seaman, Dr. Paul
Hemmes, and Dr. David Regan to retain their management and technical services,
including intellectual property necessary to develop our proposed medical
testing products. Pursuant to these agreements, we were required to issue
21,000,000 shares of our common stock to Dr. Seaman, 6,000,000 shares of our
common stock to Dr. Hemmes, and 3,000,000 shares of our common stock to Dr.
Regan in exchange for their management services and certain intellectual
property necessary to develop our proposed products and processes.

ITEM 5. OTHER EVENTS
--------------------

NAME CHANGE. On June 16, 2003, we effected a change in name from Vitatonics
Corp. to Rapid Bio Tests Corporation. The name change became effective with the
filing of a Certificate of Amendment to our Articles of Incorporation with the
Nevada Secretary of State.

CHANGES IN SECURITIES.

REVERSE SPLIT. On June 16, 2003, we also effected a reverse split of our issued
and outstanding common stock on a 1-for-250. Our Board of Directors authorized
and approved a 1-for-250 reverse stock split of our issued and outstanding
common stock. As a result of the stock split, each two hundred fifty (250)
shares of our issued and outstanding common stock was decreased to one (1) fully
paid and nonassessable share of common stock, $0.001 par value per share.
Fractional shares were rounded upward. The reverse stock split reduced the
number of shares of common stock outstanding from 28,546,972 shares as of April
24, 2003, to approximately 114,188 shares. The common stock will continue to be
$0.001 par value.

INCREASE IN AUTHORIZED COMMON STOCK. By means of filing a Certificate of
Amendment to our Articles of Incorporation on June 16, 2003, we effected an
increase in the authorized number of shares of our $.001 par value common stock
from 50,000,000 to 120,000,000 shares.

The name change, reverse split and increase in authorized shares of common stock
were approved on April 25, 2003, by unanimous approval of our Board of
Directors. In addition, shareholders holding a majority of our outstanding
common stock approved those actions by written consent in lieu of a meeting on
April 25, 2003, in accordance with the relevant sections of the Nevada Revised
Statutes.

CHANGE OF SYMBOL AND CUSIP NUMBER. Concurrent with these changes, we have a new
symbol and CUSIP Number. Our symbol changed from "VITN" to "RBIO," and our CUSIP
Number has changed from 928488-10-5 to 753339-10-0.

ITEM 6. RESIGNATIONS OF DIRECTORS.
----------------------------------

On June 16, 2003, Daniel McCormick resigned as our President and director. The
resignation is not the result of any disagreement with us on any matter relating
to our operations, policies or practices. A copy of Mr. McCormick's resignation
is filed as Exhibit 17.1 to the Form 8-K filed June 18, 2003. On June 16, 2003,
George Farquhar resigned as our Secretary, Chief Financial Officer and director.
The resignation is not the result of any disagreement with us on any matter
relating to our operations, policies or practices. A copy of Mr. Farquhar's
resignation is filed as Exhibit 17.2 to the Form 8-K filed June 18, 2003. On
June 16, 2003, Dennis McCormick resigned as our director. The resignation is not
the result of any disagreement with us on any matter relating to our operations,
policies or practices. A copy of Mr. McCormick's resignation is filed as Exhibit
17.3 to the Form 8-K filed June 18, 2003.

B. ON JULY 31, 2003, WE FILED A REPORT ON FORM 8-K TO REPORT THE FOLLOWING:


                                       14
<PAGE>



ITEM 1. CHANGES IN CONTROL.
---------------------------

On July 28, 2003, our Board of Directors voted to approve a reduction in the
number of shares issued to Drs. Seaman, Hemmes and Regan and executed Addenda to
each of the Agreements, and those Addenda were executed on July 28, 2003. These
Addenda are filed as exhibits to the report on Form 8-K filed July 31, 2003 as
Exhibits 2.1, 2.2. and 2.3 respectively. We filed the initial Agreements
attached to our report on Form 8-K which was filed on June 18, 2003; those
Agreements are attached as Exhibits 2.1, 2.2 and 2.3 to that report.

The following table sets forth certain information regarding the beneficial
ownership of our common stock as of July 28, 2003, by each person or entity
known by us to be the beneficial owner of more than 5% of the outstanding shares
of common stock, each of our directors and named executive officers, and all of
our directors and executive officers as a group.
<TABLE>
<CAPTION>
<S>                                             <C>                                    <C>                          <C>
TITLE OF CLASS             NAME AND ADDRESS OF BENEFICIAL OWNER          AMOUNT AND NATURE OF BENEFICIAL      PERCENT OF CLASS
                                                                                      OWNER
-----------------------    ------------------------------------------    ---------------------------------    -----------------
Common Stock               Geoffrey V.F. Seaman, Ph.D.                           9,000,000 shares
                           5409 Ivy Street                                   chief executive officer,              43.8%
                           Springfield, OR 97478                                     director

Common Stock               Paul Hemmes, Ph.D.                                    4,000,000 shares                  19.5%
                           5409 Ivy Street                                 secretary, treasurer, chief
                           Springfield, OR 97478                           financial officer, director

Common Stock               David H. Regan., M.D.                                 2,000,000 shares                   9.7%
                           5409 Ivy Street                                  vice president of medical
                           Springfield, OR 97478                                affairs, director

Common Stock               Margaret Seaman                                      350,000 shares(1)                   1.7%
                           5409 Ivy Street                                    independent contractor
                           Springfield, OR 97478

Common Stock               Cathy Shackleton                                      1,300,000 shares                   6.3%
                           5409 Ivy Street                                          consultant
                           Springfield, OR 97478


Common Stock               All directors and named executive                   15,350,000 shares(2)                74.6%
                           officers as a group
</TABLE>

(1) Stock holdings reflect totals after giving effect to the Addendum to each
individual's Asset Purchase and Employment Agreement reducing the number issued.
These Addenda are filed as exhibits to the report on Form 8-K filed July 31,
2003. The original Asset Purchase and Employment Agreements were filed as
exhibits to our report on Form 8-K filed on June 18, 2003. (2) Margaret Seaman
is the spouse of Geoffrey Seaman, therefore each beneficially owns 9,350,000
shares of our common stock, or 45.5% of the total issued and outstanding.
(3) Issued on July 23, 2003 pursuant to consultant and independent contractor
agreements executed with Ms. Shackleton and Ms. Seaman, which are filed as
exhibits 4.4 and 4.6 respectively to our Registration Statement on Form S-8
filed July 3, 2003. (4) This total represents the aggregate beneficial ownership
of our officers and directors as a group.

Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. In accordance with Securities and Exchange
Commission rules, shares of our common stock which may be acquired upon exercise
of stock options or warrants which are currently exercisable or which become
exercisable within 60 days of the date of the table are deemed beneficially
owned by the optionees. Subject to community property laws, where applicable,
the persons or entities named in the table above have sole voting and investment
power with respect to all shares of our common stock indicated as beneficially
owned by them.


                                       15
<PAGE>



We are not aware of any arrangements which may result in "changes in control" as
that term is defined by the provisions of Item 403 of Regulation S-B.

SUBSEQUENT REPORTS: Subsequent to the reporting period covered by this report we
filed the following current reports on Form 8-Ks:

A. On September 3, 2003 we filed a current report on Form 8-K attaching as
Exhibit 99, a press release announcing our new President, Dr. Thomas F.
Zimmerman, III.

B. On October 10, 2003, we filed a current report on Form 8-K attaching as
Exhibit 99, a press release announcing a letter of intent entered in to with Dr.
Michael Huchital to purchase by way of a formal Asset Purchase Agreement, all
rights, interests and title to a portfolio of diagnostic tests, developed or
partially developed, under development and tests under study and research.



                                       16
<PAGE>



                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

                                             Rapid Bio Tests Corporation,
                                             a Nevada corporation



October 20, 2003                    By:      /s/  Thomas F. Zimmerman
                                             ---------------------------------
                                             Thomas F. Zimmerman, III
                                    Its:     President, Director




                                       17
<PAGE>



CERTIFICATIONS
--------------

I, Geoffrey V.F. Seaman, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Rapid Bio Tests
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

          a) all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: October 20, 2003

/s/ Geoffrey V.F. Seaman
------------------------
Geoffrey V.F. Seaman
Chief Executive Officer




                                       18
<PAGE>



CERTIFICATIONS
--------------

I, Paul R. Hemmes, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Rapid Bio Tests
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

          a) all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal controls; and

          6. The registrant's other certifying officers and I have indicated in
          this quarterly report whether or not there were significant changes in
          internal controls or in other factors that could significantly affect
          internal controls subsequent to the date of our most recent
          evaluation, including any corrective actions with regard to
          significant deficiencies and material weaknesses.

Date: October 20, 2003


/s/ Paul R. Hemmes
----------------------
Paul R. Hemmes
Chief Financial Officer



                                       19
<PAGE>